Tesofensine Dosage Guide: Protocols, Calculator & Safety

Beginner Tesofensine Protocol — Low Dose, Careful Titration:

This protocol is designed for first-time users with medical supervision, baseline cardiovascular assessment, and conservative dosing. Tesofensine is NOT an appropriate first-line weight loss intervention — GLP-1 class drugs have stronger safety profiles and should be tried first. This protocol is for patients who have failed or cannot tolerate GLP-1 class and are considering tesofensine specifically, OR for research-chemical users who want the lowest-risk entry point.

Prerequisites Before Starting:

1. Baseline 12-lead ECG
2. Baseline resting heart rate (seated, 5 min rest) and blood pressure (average of 3 readings)
3. Lipid panel, fasting glucose, HbA1c
4. Pregnancy test if applicable (tesofensine not studied in pregnancy)
5. Psychiatric history assessment — rule out bipolar spectrum disorder
6. Current medication review — specifically screening for MAOIs, SSRIs, stimulants, sympathomimetics
7. Cardiovascular risk calculation (Framingham or ASCVD)
8. Realistic discussion: why tesofensine specifically vs GLP-1 alternatives?

Week 1-2 (Initial Titration):

• Dose: 0.25 mg once daily, morning
• Timing: early morning (7-9 AM) to minimize evening stimulant effect given 9-day half-life
• With or without food (oral bioavailability high either way)
• Monitoring: daily HR and BP at the same time of day for first 14 days
• Expected effects: mild appetite reduction begins within days; full effect builds over 4-6 weeks as steady state approaches

Week 3-4:

• Continue 0.25 mg daily
• Assess tolerability: any heart rate elevation >10 bpm over baseline? Any BP rise >10 mmHg systolic? Any palpitations, new anxiety, insomnia?
• If any significant adverse signal → discontinue or remain at this dose indefinitely
• If tolerated well and weight loss progress is satisfactory → stay at 0.25 mg

Week 5-8:

• If weight loss has plateaued at 0.25 mg and tolerability has been clean, consider increasing to 0.5 mg daily
• Recheck HR, BP at 1 week and 2 weeks after dose increase
• Continue weekly HR/BP monitoring

Week 9-24 (Maintenance):

• Stay at 0.5 mg daily if tolerated
• Monthly HR, BP, weight checks
• Quarterly: fasting glucose, lipids, HbA1c
• Semi-annual: ECG

Lifestyle Requirements: Tesofensine does not replace lifestyle intervention — it works best as an adjunct. Non-negotiables:

1. Caloric deficit structure: tesofensine suppresses appetite, but you still need to eat enough protein (1.2-1.6 g/kg/day) and micronutrients.
2. Resistance training: 3x/week at minimum. Aggressive weight loss without resistance training causes lean mass loss that is difficult to reverse.
3. Adequate sleep: 7-9 hours. Tesofensine may cause insomnia; if so, this is a marker to reduce dose, not ignore.
4. Hydration: 3+ L/day water. Appetite suppression often reduces fluid intake; dehydration amplifies CV side effects.
5. Alcohol moderation or elimination: alcohol worsens tesofensine insomnia and adds CV stress.

Red Flags That Require Immediate Discontinuation:

• Chest pain or pressure
• Palpitations with associated dizziness or syncope
• Severe hypertension (≥160/100 on home monitoring)
• New or worsening anxiety/panic
• Suicidal ideation or severe mood changes
• Signs of serotonin syndrome (tremor, hyperthermia, confusion, muscle rigidity)

Duration: Limit initial course to 24 weeks. At that point, reassess:

• Cumulative weight loss
• Cardiovascular trajectory (any rise in HR, BP, or symptoms?)
• Lifestyle adherence (is tesofensine enabling sustainable habits?)
• Whether to continue, transition off, or bridge to GLP-1

What to Expect:

• Appetite suppression: noticeable within 1-2 weeks; strong by week 4-6
• Weight loss: typically 6-12% at 0.5 mg over 24 weeks (from pivotal trial data)
• Energy/alertness: mild stimulant-like feel, often subjectively positive
• Sleep: some patients experience insomnia; morning dosing helps but may not fully prevent
• Mood: often mildly improved (mild antidepressant-like profile)
• Dry mouth, constipation: likely; managed with hydration and fiber

This Protocol Is NOT Appropriate If:

• You have known cardiovascular disease or arrhythmias
• Blood pressure is poorly controlled (>140/90)
• Resting HR is >90 bpm at baseline
• You're taking MAOIs, SSRIs, SNRIs, or stimulants
• You have bipolar disorder or severe anxiety
• You're pregnant, breastfeeding, or actively trying to conceive
• You're under 18 or over 70
• You drink more than 1-2 alcoholic drinks daily

Intermediate Tesofensine Protocol — Optimized Dosing with CV Management:

This protocol is for patients who have tolerated the beginner 0.25-0.5 mg phase cleanly for at least 8-12 weeks and are considering higher-dose use for plateau-breaking or accelerated results. It assumes a medical oversight relationship with ECG/BP/HR monitoring capability and builds in active CV management.

Prerequisite Status:

• Successfully completed beginner protocol
• HR increase from baseline <10 bpm
• BP stable
• ECG unchanged at 8-12 week recheck
• No significant adverse neuropsychiatric effects

Phase 1 (Weeks 1-4): Escalation to 0.75 mg

• Dose increase: 0.5 mg → 0.75 mg daily
• Timing: maintain morning dosing
• Monitoring intensifies: HR/BP 2x daily (morning and evening) for 2 weeks
• Expect new steady state in 4-6 weeks

Phase 2 (Weeks 5-12): 0.75 mg Maintenance OR Escalation to 1.0 mg

• Assess at week 4: is 0.75 mg producing continued weight loss?
• If yes: stay at 0.75 mg — the dose-response curve is not steep enough to automatically justify the higher dose
• If weight loss has plateaued AND CV parameters remain favorable → consider 1.0 mg
• Before escalating to 1.0 mg: repeat ECG, consider 24-hour ambulatory BP monitoring, discuss CV risk explicitly

1.0 mg Dose — The Trial Data Sweet Spot AND the CV Risk Zone: The pivotal trial's largest weight loss was at 1.0 mg, but so was the largest HR increase. This dose is where risk-benefit requires careful personal calibration:

• Heart rate: expect 5-10 bpm increase from previous 0.5 mg baseline
• Blood pressure: monitor for sustained >5 mmHg systolic increase
• Subjective stimulant effects: more pronounced; may worsen sleep, anxiety

CV Management Strategies at 1.0 mg:

Strategy A: Monotherapy with intensive monitoring

• Daily morning HR check before dose
• Weekly BP logs
• Monthly ECG for first 3 months
• Immediate dose reduction if HR >90 bpm resting or BP >140/90 sustained

Strategy B: Combination with low-dose beta-blocker (Tesomet-inspired)

• Add metoprolol tartrate 25-50 mg BID OR atenolol 25 mg daily
• Rationale: beta-blocker blunts the HR elevation without interfering with appetite effects
• Monitor: confirm HR now in acceptable range; watch for beta-blocker effects (fatigue, exercise intolerance)
• This is the approach Saniona took with their Tesomet formulation in Mexico
• Requires medical prescription and oversight

Strategy C: Pulsed / Cycling Approach

• 5 days on, 2 days off (using the long half-life to your advantage)
• 2-day pause doesn't meaningfully affect plasma levels given 9-day half-life, but the psychological reset and slight sympathetic recovery may be beneficial
• Not formally studied; based on long-half-life pharmacokinetics

Weight Loss Plateau Management: Tesofensine weight loss typically plateaus after 16-24 weeks as compensatory adaptations emerge:

• Metabolic adaptation (reduced RMR)
• Appetite counter-regulation (though blunted by tesofensine)
• Behavioral adherence drift

Anti-Plateau Tactics:

1. Refeed/diet break: 1-2 week maintenance calorie period
2. Exercise variation: resistance training progression; add HIIT (check CV tolerability first)
3. Sleep audit: poor sleep amplifies weight loss plateau
4. Macronutrient cycling: slightly higher carb days on training days
5. GLP-1 bridge: transition to Semaglutide or Tirzepatide for additive mechanism
6. Avoid: adding more stimulants, more caloric restriction below 1200 kcal/day, adding other serotonergic agents

Transitioning Off: Given tesofensine's 9-day half-life, wash-out is inherently gradual:

• Dose taper over 2-4 weeks is unnecessary pharmacokinetically but provides psychological structure
• 4-6 week plasma decline after last dose
• Monitor for weight regain, appetite return, sleep normalization
• If long-term pharmacotherapy indicated, bridge to GLP-1 while tesofensine clears

Combination Strategies (Intermediate):

• Tesofensine + metformin: safe, complementary; metformin supports insulin sensitivity during weight loss
• Tesofensine + Tirzepatide: unstudied combination; if attempted, requires intense CV monitoring and gradual introduction of the second agent
• Tesofensine + resistance training + high protein: gold standard for body composition during active phase
• Tesofensine + Tesamorelin for visceral fat: theoretically complementary; minimal formal evidence

Expected Outcomes at Intermediate:

• Total weight loss 12-18% possible at 24-48 weeks of 0.75-1.0 mg
• Body composition: meaningful fat loss; lean mass preservation dependent on training + protein
• Metabolic markers: favorable changes in lipids, glucose
• CV trajectory: key variable — if favorable, tesofensine is "working as designed"; if unfavorable, dose reduction mandatory

This Protocol Is NOT Appropriate If:

• Beginner protocol showed >10 bpm HR increase or BP instability
• Any new CV symptoms developed
• Psychiatric symptoms emerged
• You don't have reliable access to ECG and medical oversight

Advanced Tesofensine Protocol — Expert Combination Strategies and Long-Term Use:

This protocol addresses scenarios where tesofensine is used for >6 months, combined with other therapeutics, or applied to specific body composition goals. It assumes full medical oversight, sophisticated CV monitoring, and explicit acknowledgment that long-term tesofensine safety data (beyond 52 weeks) are sparse.

Prerequisites:

• Minimum 6 months on beginner + intermediate protocols with clean tolerance
• Intact medical supervision relationship
• Recent (within 3 months) echocardiogram and 24-hour ambulatory BP monitoring
• Clear long-term plan (not open-ended use)

Long-Term Use Considerations:

The "52+ Week" Evidence Gap: The pivotal TIPO-1 trial was 24 weeks. TIPO-3 extension data exists for ~48 weeks total in a subset of patients with generally maintained effect. Beyond 52 weeks, published clinical trial evidence is limited. Real-world use in Mexico (Tesomet approval) provides some post-marketing data but is not equivalent to controlled trial evidence.

Long-Term CV Monitoring Schedule:

• Months 6-12: monthly HR/BP, quarterly ECG
• Months 12-24: quarterly HR/BP/ECG, annual echocardiogram
• Years 2+: semi-annual ECG, annual echo, ambulatory BP when any symptom changes

Dose Strategies for Long-Term Use:

Strategy 1: Sustained Effective Dose

• Maintain 0.5-0.75 mg indefinitely as long as CV parameters remain favorable and weight loss is sustained or maintenance-appropriate
• Tolerance to appetite effect is modest but exists; dose may need slight increase at 12-18 months if appetite returns

Strategy 2: Intermittent Long-Term

• 12-16 weeks on, 4-6 weeks off
• During off-periods, maintain lifestyle without tesofensine; reassess whether to restart
• Useful for patients who want pharmacologic support for weight maintenance but don't want continuous exposure
• Not formally validated but pharmacokinetically sensible

Strategy 3: Dose Reduction to Maintenance

• After significant weight loss achieved, reduce to 0.25 mg for long-term maintenance
• Lower CV signal at this dose
• Mild continued appetite effect
• Best evidence is absent, but mechanistically reasonable

Complex Combinations (Expert-Only):

Tesofensine + GLP-1 Agonist:

• Rationale: non-overlapping mechanisms, potentially additive weight loss
• Approach: establish stable tesofensine dose first, then introduce Semaglutide at lowest dose (0.25 mg weekly) and slow titration
• Monitoring: CV parameters tighten (both drugs affect CV system differently), GI tolerability (GLP-1-related)
• Expected outcome: weight loss 20-30% possible but with compounded side effects; nutritional adequacy concerns amplify
• Duration: limit to 6-12 months at dual therapy, then consolidate to one agent

Tesofensine + Tesamorelin (for Visceral Fat Focus):

• Rationale: Tesamorelin specifically targets visceral adipose via GHRH stimulation; tesofensine provides general weight loss
• Protocol: tesamorelin 2 mg SC daily; tesofensine 0.5 mg PO daily
• Monitoring: glucose (tesamorelin can affect insulin sensitivity), CV (tesofensine)
• Duration: 6 months per tesamorelin cycle, with tesofensine continuous or cycled

Tesofensine + Body Recomposition Stack: For physique-focused goals, some users attempt:

• Tesofensine 0.5-0.75 mg (appetite suppression, mild thermogenesis)
• Ipamorelin + CJC-1295 (GH pulse; lean mass support)
• Modafinil or similar (cognitive performance during caloric deficit) — CAUTION: additive CV
• Creatine, adequate protein, resistance training

This aggressive stack has almost no controlled evidence; CV risk compounds meaningfully; not recommended for non-competitive/non-supervised use.

Specialized Applications:

Hypothalamic Obesity: Patients with craniopharyngioma surgery or hypothalamic damage have a subtype of obesity essentially refractory to standard interventions. Tesofensine shows efficacy in this population and represents one of the few pharmacologic options. Phase 2 trials have supported this use. Protocol parallels standard intermediate dosing with continuous CV monitoring.

Prader-Willi Syndrome: Tesomet (tesofensine + metoprolol) achieved Mexican approval for Prader-Willi obesity. Protocol follows approved labeling; supervised by specialty clinics.

Post-Bariatric Weight Regain: Tesofensine as pharmacologic adjunct to address weight regain after bariatric surgery. Unvalidated but mechanistically plausible; CV risk considerations amplified post-surgery.

Safety Infrastructure for Advanced Use:

Baseline Documentation:

• Echocardiogram within 6 months
• Ambulatory BP monitoring
• Detailed CV risk calculation
• Lipid panel, HbA1c
• Psychiatric evaluation
• Substance use screening

Adverse Event Response Protocol:

• Define specific thresholds for dose reduction, dose pause, full discontinuation
• Written plan for emergency symptoms (chest pain, severe palpitations, stroke signs)
• Access to rapid medical consultation during active use

Exit Planning:

• Every tesofensine course should have a defined exit plan
• Most appropriate exit: transition to sustainable lifestyle + bridge to GLP-1 if long-term pharmacotherapy needed
• Weight regain is expected without sustained intervention; plan for it proactively

Long-Term Realistic Expectations:

• Sustained 10-18% weight loss at 12 months achievable for many patients
• Plateau generally occurs between 6-12 months
• Weight regain after discontinuation is near-universal without sustained behavioral intervention
• CV trajectory is the primary long-term concern; most "failure" modes involve CV signal emerging rather than loss of efficacy
• Not a "forever drug" for most patients — durability is limited by both efficacy plateau and safety concerns

When Advanced Use Is Not Appropriate:

• Any stability concerns on CV monitoring
• Inadequate medical oversight infrastructure
• Psychiatric instability
• Concurrent substance use that complicates monitoring
• Inability to maintain nutritional adequacy during aggressive weight loss
• Patient unable or unwilling to engage with resistance training and lifestyle adjuncts